Medical / Pharmaceuticals
Releases published in the last 30 days. 
Page 1 of 2
- Survey shows need to rebuild trust in evidence-based health information
- 3/6/2026 10:23:22 AM
- New survey findings from the Annenberg Public Policy Center highlight a widening trust gap in the nation’s health information landscape and underscore the importance of trusted medical voices grounded in science.
- AdvaMed® Announces Opening Nominations for its 2026 Lifetime Achievement, Dx Lifetime of Leadership & Service, and theAdvaMed® Imaging Röntgen Awards
- 3/6/2026 10:11:12 AM
- AdvaMed® announced that nominations for its 2025 Lifetime Achievement Award as well as the AdvaMedDx Lifetime of Leadership & Service Award and theAdvaMed® Imaging Röntgen Award are open through April 10.
- Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
- 3/5/2026 8:00:16 PM
- The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the renewal of the mandates of Christophe Babule and Jean-Paul Kress. Patrick Kron, independent director and Chairman of the Nomination, Governance and CSR …
- Thermo Fisher Scientific Expands Immunodiagnostics Operations with New Distribution and Labeling Center in Uppsala
- 3/4/2026 9:24:45 AM
- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of a new 8,000-square-meter distribution and labeling center supporting its immunodiagnostics business in Uppsala.
- WHO calls for a global shift to environmentally friendly, less invasive and affordable oral health care
- 3/4/2026 9:13:58 AM
- The World Health Organization has released a new global guideline, Environmentally friendly and less invasive oral health care for preventing and managing dental caries.
- Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
- 3/4/2026 8:51:54 AM
- Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven …
- How some skills become second nature
- 3/4/2026 4:56:09 AM
- Expertise isn’t easy to pass down. Take riding a bike: A seasoned cyclist might talk a beginner through the basics of how to sit and when to push off.
- SUDAN: First vaccine shipment in nearly three years arrives in South Kordofan
- 3/3/2026 1:25:01 PM
- The first shipment of vaccines to South Kordofan, Sudan in nearly three years will restore lifesaving immunization services to children and communities cut off from essential supplies due to conflict and siege, Save the Children said.
- Government Expands GLP-1 Access — Menu-Order-AI Powers Everyday Decision Support
- 3/3/2026 1:13:52 PM
- The Centers for Medicare & Medicaid Services (CMS) has announced the BALANCE Model, a voluntary initiative designed to expand access to GLP-1 medications under Medicare and Medicaid through negotiated pricing and structured coverage.
- WHO releases updated Health Inequality Data Repository and Health Equity Assessment Toolkit
- 3/3/2026 11:14:23 AM
- WHO has released updated versions of two key resources as part of the Health Inequality Monitor to strengthen data accessibility and usability for health equity.
- Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
- 3/2/2026 7:20:47 PM
- • Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD • Third global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible …
- Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
- 2/27/2026 11:47:14 PM
- • If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment • CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children The European Medicines Agency’s …
- Have abortion-related laws affected broader access to maternal health care?
- 2/26/2026 10:08:39 AM
- Since 2010, increasing numbers of states across the US have enacted Targeted Regulation of Abortion Providers (TRAP) laws that require abortion clinics to adhere to stringent and often medically unnecessary standards.
- GSMA Foundry and NUHS Singapore to drive 5G and AI innovations in healthcare through new strategic partnership
- 2/26/2026 2:25:42 AM
- The GSMA announced a strategic agreement between GSMA Foundry, the mobile industry’s collaborative innovation hub, and Singapore’s National University Health System (NUHS), a fully integrated academic and regional health system that delivers value-driven, innovative and sustainable healthcare in Singapore.
- ATRO Medical Secures €3 Million to Advance Artificial Meniscus Toward Pivotal Studies
- 2/25/2026 10:03:03 AM
- ATRO Medical, the Dutch clinical-stage orthopedic company developing a novel artificial meniscus implant for patients suffering from post-meniscectomy pain, today announces the successful closing of a €3 million financing round.
- Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
- 2/24/2026 3:49:45 PM
- • Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placebo • AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high …
- Does mental health affect mortality risk in adults with cancer?
- 2/24/2026 11:20:12 AM
- In a study of adults with cancer, those who developed a mental health condition within the first year after their cancer diagnosis had a higher likelihood of dying over the next few years.
- Blackstone Life Sciences Announces a Co-funding Agreement for Acute Myeloid Leukemia
- 2/23/2026 10:46:14 AM
- Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”).
- Next-generation influenza vaccines could save millions of lives, finds WHO
- 2/20/2026 10:38:03 AM
- Next generation influenza vaccines that provide broader and longer-lasting protection than existing seasonal vaccines, could play a vital role in reducing the global burden of influenza, according to a recent World Health Organization (WHO) assessment.
- Capsadyn® Launches on Amazon, Offering Non-Burning Capsaicin Pain Relief
- 2/19/2026 8:56:39 PM
- Capsadyn®, a non-burning capsaicin cream developed by Chorda Pharma Inc., is now available for purchase on Amazon in addition to direct-to-consumer sales through Capsadyn.com.